Lombard Odier Asset Management Europe Ltd Has $11.87 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Lombard Odier Asset Management Europe Ltd grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 38.3% during the 1st quarter, Holdings Channel.com reports. The firm owned 69,585 shares of the medical research company’s stock after buying an additional 19,255 shares during the quarter. Lombard Odier Asset Management Europe Ltd’s holdings in IQVIA were worth $11,867,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in IQV. Franklin Street Advisors Inc. NC acquired a new stake in IQVIA in the fourth quarter valued at approximately $15,724,000. CWM LLC raised its position in shares of IQVIA by 23.9% during the fourth quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock worth $12,585,000 after purchasing an additional 10,762 shares during the period. Calamos Advisors LLC lifted its holdings in shares of IQVIA by 268.1% in the 4th quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after purchasing an additional 137,441 shares in the last quarter. Assetmark Inc. grew its position in IQVIA by 33.6% in the 4th quarter. Assetmark Inc. now owns 172,625 shares of the medical research company’s stock valued at $38,911,000 after purchasing an additional 43,436 shares during the period. Finally, KBC Group NV increased its stake in IQVIA by 68.2% during the 4th quarter. KBC Group NV now owns 779,128 shares of the medical research company’s stock valued at $175,624,000 after purchasing an additional 315,883 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.0%

Shares of IQV opened at $235.09 on Monday. The business has a 50-day moving average of $194.75 and a 200 day moving average of $186.82. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $251.36. The firm has a market cap of $38.70 billion, a P/E ratio of 29.17, a price-to-earnings-growth ratio of 1.99 and a beta of 1.20. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter last year, the company earned $2.81 earnings per share. The company’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 11.61 EPS for the current year.

IQVIA declared that its board has authorized a stock buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Mizuho raised their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Robert W. Baird upped their target price on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a research report on Thursday, July 9th. HSBC reissued a “buy” rating and set a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. Finally, JPMorgan Chase & Co. increased their price objective on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $241.88.

Trending Headlines about IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: William Blair upgraded IQVIA to “strong buy,” adding to the favorable analyst outlook. Ticker Report article
• Positive Sentiment: Robert W. Baird raised its IQVIA price target to $287, implying substantial upside from the cited trading level. JPMorgan and Stifel Nicolaus also expressed expectations for further appreciation. American Banking News article on Baird price target American Banking News article on JPMorgan forecast American Banking News article on Stifel outlook
• Positive Sentiment: IQVIA’s second-quarter results exceeded expectations, with adjusted earnings of $3.15 per share versus the $3.03 consensus and revenue of $4.37 billion versus $4.30 billion expected. Revenue increased 8.7% year over year, reinforcing the company’s growth profile. IQVIA Q2 2026 earnings call summary
• Neutral Sentiment: Analysts maintain a “moderate buy” consensus, indicating generally favorable sentiment but not unanimous conviction. IQVIA analyst consensus article
• Negative Sentiment: Two insiders sold shares on July 29: Keriann Cherofsky sold 558 shares for approximately $136,827, while Eric Sherbet sold 5,000 shares for about $1.25 million. Although both retain meaningful holdings, the transactions may create short-term investor concern. SEC insider sale filing for Keriann Cherofsky SEC insider sale filing for Eric Sherbet

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.